0001401914-26-000026
SEC filingRevenue surged nearly 500% year-over-year to $152.5K, driven by new Gates Foundation service agreements — not commercial product sales — while operating and net losses narrowed modestly as the company continues advancing its women’s health pipeline amid ongoing going-concern uncertainty.
Revenue of $152.5K reflects the commencement of two Gates Foundation service agreements in November 2025 — one for preeclampsia mentorship and another for contraceptive landscape review. These are fee-for-service arrangements, not product sales or royalties. XACIATO royalties ceased after the April 2024 sale to XOMA, and no commercial product revenue was recognized in Q1 FY2026. The 499.6% year-over-year increase is therefore attributable solely to the timing of contract initiation and does not signal commercial traction or scale.
Gross profit was -$89.9K, yielding a gross margin of -58.9%. This negative margin arises from direct costs associated with delivering the Gates Foundation services — including personnel, subcontractor, and program-specific overhead — exceeding the related revenue. It reflects the early-stage, cost-intensive nature of service execution and confirms the absence of any commercial product revenue stream that would contribute positively to gross margin.
Operating income improved to -$3.0M (a 34.5% improvement YoY), and net income improved to -$3.0M (a 31.5% improvement YoY). These improvements reflect lower absolute losses compared to Q1 FY2025, but not a reduction in operational intensity: the company continues active development across Ovaprene, DARE-HPV, and DARE-LARC1, as confirmed by management commentary on future operating expense growth and ARPA-H award support for the planned Phase 2 study. The narrowing losses stem from higher revenue offsetting fixed cost structures, not decreased R&D activity.
Net cash used in operating activities was -$5.5M, nearly unchanged from -$5.5M in Q1 FY2025. Capital expenditures were $0, confirming no material asset acquisition or build-out occurred during the quarter. This aligns with the company’s current stage: advancing clinical and regulatory programs without significant infrastructure investment. The absence of CapEx reinforces that resource allocation remains focused on R&D execution rather than scaling manufacturing or commercial operations.